At what enterprise value was GLYCOM acquired in 2020?

During the acquisition of GLYCOM by ROYAL DSM in 2020, the company was valued at an estimated revenue multiple of 10x - 18x. The transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of GLYCOM when it was acquired by ROYAL DSM?

The estimated EV/EBITDA multiple for GLYCOM is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was GLYCOM acquired by ROYAL DSM?

GLYCOM was acquired by ROYAL DSM in 2020.

What was the revenue of GLYCOM at the time of the deal?

The revenue of GLYCOM at the time of the deal is estimated to be in the range of 50M - 100M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of GLYCOM during the acquisition?

GLYCOM's EBITDA is estimated to be in the range of 25M - 50M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the GLYCOM acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the GLYCOM deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://our-company.dsm-firmenich.com/en/our-company/news/press-releases/legacy-archive/2020/10-20-dsm-to-acquire-glycom-to-accelerate-growth-in-early-life-nutrition.html

← DATABASE

Home Database Healthcare & PharmaGLYCOM

04/2020

GLYCOM acquired by ROYAL DSM

DENMARK Life Sciences / Nutrition & Dietary Supplements EV 500M - 1.5b EUR

Context

Royal DSM reached an agreement to acquire 100% of Glycom A/S. The strategic rationale for the acquisition is to accelerate DSM’s growth in the Early Life Nutrition (ELN) segment by adding HMOs (a novel, high-growth ingredient) to its portfolio. DSM intends to leverage its global sales force to offer Glycom’s HMOs to its broad customer base, reducing Glycom’s historical dependency on a single major customer (Nestlé). Furthermore, DSM aims to utilize its R&D and clinical competencies to speed up the development of next-generation HMOs and introduce these ingredients into new markets such as medical nutrition and pet food. The acquisition is expected to be highly synergetic, with DSM targeting an EBITDA contribution and EPS accretion of €0.10–€0.15 by 2021 as the "SaaS-like" recurring revenue from long-term supply contracts scales up.

GLYCOM, which reported an EBITDA margin of LOGIN in 2019, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2005, Glycom is the world's leading supplier of Human Milk Oligosaccharides (HMOs). HMOs are complex carbohydrates found in breast milk that act as essential prebiotics for infant immune and cognitive development. Glycom is the only fully integrated HMO provider globally, encompassing product development, preclinical/clinical research, and large-scale manufacturing at its state-of-the-art plant in Esbjerg, Denmark. The company pioneered the commercialization of HMOs for the Early Life Nutrition (ELN) market, with Nestlé serving as its primary long-term customer. Glycom’s value proposition lies in its unique IP portfolio and its "innovation roadmap" for next-generation HMOs. Its strategy focuses on providing high-purity, science-based ingredients that allow infant formula manufacturers to more closely mimic the nutritional profile of human breast milk.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2019

2018

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
09/2020	EQT PARTNERS	SCHÜLKE	GERMANY	Life Sciences	EQT completed the acquisition of 100% of Schülke from its parent company, Air Liquide. This transaction represents a strategic carve-out for Air Liquide, allowing the French industrial gas giant to refocus on its core activities while providing Schülke with the independent capital necessary for long-term expansion
06/2020	AVISTA CAPITAL PARTNERS	VISION HEALTHCARE	BELGIUM	Life Sciences	The acquisition of Vision Healthcare NV by Avista Capital Partners marks a significant milestone in the company's strategic journey. The partnership enables Vision to realize further rapid growth and make additional investments that leverage its differentiated direct-to-consumer business model
04/2020	WARBURG PINCUS	POLYPLUS	France	Life Sciences	Warburg Pincus has acquired a 50% co-control stake in Polyplus from ArchiMed, executing a flagship LBO in the European mid-cap space. The transaction structure is characterized by a significant reinvestment from the incumbent sponsor, ArchiMed, ensuring that both private equity firms hold equal equity stakes and voting rights post-closing
04/2020	AMERICAN SECURITIES	PARAGON MEDICAL	UNITED STATES	Life Sciences	The divestiture of the Life Sciences division by NN inc. (Paragon Medical) to American Securities represents a pivotal structural transformation for both organizations. For the seller, the transaction provides a necessary capital infusion to significantly reduce corporate debt and reposition its remaining industrial platform toward power and mobile solutions
03/2020	LBO FRANCE	DUTSCHER	FRANCE	Life Sciences	LBO France acquired a controlling stake in Dutscher, replacing Five Arrows (who had held the majority since 2014). This Secondary LBO also marked the exit of the founder's son, who held ~40% but had no operational role, completing the transition from a family-owned business to a financial-backed platform
02/2020	TETHYS INVEST / PSP INVESTMENTS / MITSUI & CO	CEVA SANTE ANIMALE	FRANCE	Life Sciences	Ceva Sante Animale completed a historic "Jumbo LBO". This transaction allowed the management team (800+ executives) to retain over 50% of the capital—a record for a deal of this size in France (comparable only to the Legrand buyout in 2002)
02/2020	PERRIGO COMPANY	HIGH RIDGE BRANDS (ORAL CARE PORTFOLIO)	UNITED STATES	Life Sciences	The acquisition of the High Ridge Brands Oral Care assets by Perrigo signifies a definitive densification of the group’s specialized hygiene division. The strategic rationale for this transaction hinges on a "category-dominance" maneuver, merging the target’s technical operational depth in the branded-value children’s segment with the acquirer’s massive Ranir platform
10/2019	DENTRESSANGLE	MARLE GROUP	FRANCE	Life Sciences	Dentressangle has entered into exclusive negotiations to acquire a majority stake in Marle Group from IK Investment Partners on a preemptive basis, successfully securing the asset outside of a traditional, highly competitive auction process
09/2019	SAGARD	STERIMED	FRANCE	Life Sciences	Sterimed, a global leader in medical sterilization packaging, has entered into exclusive negotiations with Sagard to organize a secondary LBO. This transaction facilitates the exit of Meeschaert Capital Partners, which held a majority stake since 2016 following the group's spin-off from ArjoWiggins
08/2019	PERMIRA	CAMBREX CORPORATION	UNITED STATES	Life Sciences	Permira, the global private equity firm, successfully completed the acquisition of Cambrex Corporation, a premier small molecule CDMO, in a take-private transaction that signaled a major consolidation move in the pharmaceutical services sector

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 50M - 100M EUR

EBITDA range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of GLYCOM by ROYAL DSM are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).